Drawing for DEVELOPING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY

USPTO serial 87623179

DEVELOPING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY

Reviewed by CopyMark Law Group

Reg. 5700399Status 710
Filing date
Status date
Registration date
Mar 19, 2019
Examiner
MARSH, BRANDON N
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with DEVELOPING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Melanie Howard

MELANIE HOWARD LOEB & LOEB LLP10100 SANTA MONICA BLVD., SUITE 2200LOS ANGELES, CA 90067UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disordersSECTION 8 - CANCELLED—
042Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaidSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 3, 2025C8..CANCELLED SEC. 8 (6-YR)—
Mar 19, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Mar 19, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 1, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 1, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 12, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 28, 2018ADBS1(B) BASIS DELETED; NEW BASIS REQUESTED—
Nov 28, 2018IUCNNOTICE OF ALLOWANCE CANCELLED—
Nov 9, 2018ATRQATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED—
Nov 9, 2018PCBGPETITION TO DIRECTOR - CHANGE BASIS - GRANTED—
Nov 8, 2018APETASSIGNED TO PETITION STAFF—
Oct 10, 2018TPADTEAS PETITION TO AMEND BASIS RECEIVED—
Jun 26, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 1, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 1, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 11, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 26, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 2, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 1, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 1, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 3, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 3, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 3, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 3, 2018DOCKASSIGNED TO EXAMINER—
Sep 30, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 29, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance